An inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac. After oral administration, sulindac undergoes extensive biotransformation including irreversible oxidation to sulindac sulfone. Approximately, one half of an administered dose of sulindac is eliminated through the urine, mostly as the conjugated sulfone metabolite. Check foractive clinical trials using this agent. or A drug being studied in the treatment and prevention of cancer. It has been shown to cause apoptosis (cell death) in cells that are malignant (cancer) and in cells that may become cancer. It acts through a group of cellular enzymes called cGMP phosphodiesterases.